Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he touches on the innovation ecosystem in Spain and how 3P works with clients, rather than for them, to achieve long-term success.
The original idea was for 3P to be a pure manufacturing plant for biologic molecules, but what we have done is incorporate the idea of product and process development into our operations, moving from a CMO to a CDMO
